155 related articles for article (PubMed ID: 21946898)
1. Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in the Rotterdam Study.
Elens L; Becker ML; Haufroid V; Hofman A; Visser LE; Uitterlinden AG; Stricker BCh; van Schaik RH
Pharmacogenet Genomics; 2011 Dec; 21(12):861-6. PubMed ID: 21946898
[TBL] [Abstract][Full Text] [Related]
2. No effect of CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) on lipid-lowering response to statins in Greek patients with primary hypercholesterolemia.
Ragia G; Kolovou V; Tavridou A; Elens L; Tselepis AD; Elisaf M; Van Schaik RH; Kolovou G; Manolopoulos VG
Drug Metab Pers Ther; 2015 Mar; 30(1):43-8. PubMed ID: 25274942
[TBL] [Abstract][Full Text] [Related]
3. Influence of genetic variation in CYP3A4 and ABCB1 on dose decrease or switching during simvastatin and atorvastatin therapy.
Becker ML; Visser LE; van Schaik RH; Hofman A; Uitterlinden AG; Stricker BH
Pharmacoepidemiol Drug Saf; 2010 Jan; 19(1):75-81. PubMed ID: 19802823
[TBL] [Abstract][Full Text] [Related]
4. The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment.
Fiegenbaum M; da Silveira FR; Van der Sand CR; Van der Sand LC; Ferreira ME; Pires RC; Hutz MH
Clin Pharmacol Ther; 2005 Nov; 78(5):551-8. PubMed ID: 16321621
[TBL] [Abstract][Full Text] [Related]
5. Association of cytochromes P450 3A4*22 and 3A5*3 genotypes and polymorphism with response to simvastatin in hypercholesterolemia patients.
Elalem EG; Jelani M; Khedr A; Ahmad A; Alaama TY; Alaama MN; Al-Kreathy HM; Damanhouri ZA
PLoS One; 2022; 17(7):e0260824. PubMed ID: 35839255
[TBL] [Abstract][Full Text] [Related]
6. Lack of association of the p450 oxidoreductase *28 single nucleotide polymorphism with the lipid-lowering effect of statins in hypercholesterolemic patients.
Ragia G; Kolovou V; Tavridou A; Elens L; Tselepis AD; Elisaf M; Van Schaik RH; Kolovou G; Manolopoulos VG
Mol Diagn Ther; 2014 Jun; 18(3):323-31. PubMed ID: 24430948
[TBL] [Abstract][Full Text] [Related]
7. Genetic variation in the PPARA gene is associated with simvastatin-mediated cholesterol reduction in the Rotterdam Study.
de Keyser CE; Becker ML; Uitterlinden AG; Hofman A; Lous JJ; Elens L; Visser LE; van Schaik RH; Stricker BH
Pharmacogenomics; 2013 Aug; 14(11):1295-304. PubMed ID: 23930676
[TBL] [Abstract][Full Text] [Related]
8. No association between CYP3A4*22 and statin effectiveness in reducing the risk for myocardial infarction.
Leusink M; de Keyser CE; Onland-Moret NC; Hofman A; Visser LE; Stricker BH; de Bakker PI; de Boer A; van Schaik RH; Maitland-van der Zee AH
Pharmacogenomics; 2014 Aug; 15(11):1471-7. PubMed ID: 25303298
[TBL] [Abstract][Full Text] [Related]
9. Common variants of HMGCR, CETP, APOAI, ABCB1, CYP3A4, and CYP7A1 genes as predictors of lipid-lowering response to atorvastatin therapy.
Poduri A; Khullar M; Bahl A; Sehrawat BS; Sharma Y; Talwar KK
DNA Cell Biol; 2010 Oct; 29(10):629-37. PubMed ID: 20578904
[TBL] [Abstract][Full Text] [Related]
10. Hepatic metabolism and transporter gene variants enhance response to rosuvastatin in patients with acute myocardial infarction: the GEOSTAT-1 Study.
Bailey KM; Romaine SP; Jackson BM; Farrin AJ; Efthymiou M; Barth JH; Copeland J; McCormack T; Whitehead A; Flather MD; Samani NJ; Nixon J; Hall AS; Balmforth AJ;
Circ Cardiovasc Genet; 2010 Jun; 3(3):276-85. PubMed ID: 20207952
[TBL] [Abstract][Full Text] [Related]
11. Ile118Val genetic polymorphism of CYP3A4 and its effects on lipid-lowering efficacy of simvastatin in Chinese hyperlipidemic patients.
Wang A; Yu BN; Luo CH; Tan ZR; Zhou G; Wang LS; Zhang W; Li Z; Liu J; Zhou HH
Eur J Clin Pharmacol; 2005 Feb; 60(12):843-8. PubMed ID: 15650881
[TBL] [Abstract][Full Text] [Related]
12. Interactions between CYP3A5*3 and POR*28 polymorphisms and lipid lowering response with atorvastatin.
Wei KK; Zhang LR
Clin Drug Investig; 2015 Sep; 35(9):583-91. PubMed ID: 26293521
[TBL] [Abstract][Full Text] [Related]
13. Apolipoprotein E genotypes are associated with lipid-lowering responses to statin treatment in diabetes: a Go-DARTS study.
Donnelly LA; Palmer CN; Whitley AL; Lang CC; Doney AS; Morris AD; Donnan PT
Pharmacogenet Genomics; 2008 Apr; 18(4):279-87. PubMed ID: 18334912
[TBL] [Abstract][Full Text] [Related]
14. Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitors' dose requirements and trough blood levels in stable renal transplant patients.
Elens L; van Schaik RH; Panin N; de Meyer M; Wallemacq P; Lison D; Mourad M; Haufroid V
Pharmacogenomics; 2011 Oct; 12(10):1383-96. PubMed ID: 21902502
[TBL] [Abstract][Full Text] [Related]
15. Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs.
Wang D; Guo Y; Wrighton SA; Cooke GE; Sadee W
Pharmacogenomics J; 2011 Aug; 11(4):274-86. PubMed ID: 20386561
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenetic study of statin therapy and cholesterol reduction.
Chasman DI; Posada D; Subrahmanyan L; Cook NR; Stanton VP; Ridker PM
JAMA; 2004 Jun; 291(23):2821-7. PubMed ID: 15199031
[TBL] [Abstract][Full Text] [Related]
17. Common genetic variation in the ABCB1 gene is associated with the cholesterol-lowering effect of simvastatin in males.
Becker ML; Visser LE; van Schaik RH; Hofman A; Uitterlinden AG; Stricker BH
Pharmacogenomics; 2009 Nov; 10(11):1743-51. PubMed ID: 19891551
[TBL] [Abstract][Full Text] [Related]
18. CYP3A4 intronic SNP rs35599367 (CYP3A4*22) alters RNA splicing.
Wang D; Sadee W
Pharmacogenet Genomics; 2016 Jan; 26(1):40-3. PubMed ID: 26488616
[TBL] [Abstract][Full Text] [Related]
19. Co-medication of statins and CYP3A4 inhibitors before and after introduction of new reimbursement policy.
Devold HM; Molden E; Skurtveit S; Furu K
Br J Clin Pharmacol; 2009 Feb; 67(2):234-41. PubMed ID: 19220274
[TBL] [Abstract][Full Text] [Related]
20. A paucimorphic variant in the HMG-CoA reductase gene is associated with lipid-lowering response to statin treatment in diabetes: a GoDARTS study.
Donnelly LA; Doney AS; Dannfald J; Whitley AL; Lang CC; Morris AD; Donnan PT; Palmer CN
Pharmacogenet Genomics; 2008 Dec; 18(12):1021-6. PubMed ID: 18815589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
